“An Update on the Long-Term Safety Experience of Ixekizumab: Results from the Psoriasis Clinical Development Program with More than 3 Years of Follow-up from 12 Clinical Trials and More Than 15000 Patient-Years of Exposure to Ixekizumab”, J of Skin, vol. 2, p. S116, Dec. 2018, doi: 10.25251/skin.2.supp.105.